These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 15577535)

  • 41. Report from the 12th Retrovirus Conference. Vaccines, microbicides, and novel prophylactic interventions.
    Albrecht H; del Rio C
    AIDS Clin Care; 2005 Apr; 17(4):42, 44. PubMed ID: 15880874
    [No Abstract]   [Full Text] [Related]  

  • 42. Gender, age, and ethnicity in HIV vaccine-related research and clinical trials: report from a WHO-UNAIDS consultation, 26-28 August 2004. Lausanne, Switzerland.
    WHO-UNAIDS Expert Group
    AIDS; 2005 Nov; 19(17):w7-28. PubMed ID: 16260898
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The rocky road to an AIDS vaccine.
    Osborn JE
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 May; 9(1):26-9. PubMed ID: 7712231
    [No Abstract]   [Full Text] [Related]  

  • 44. The HIV/AIDS pandemic--virology update.
    van Rensburg EJ
    SADJ; 2002 Dec; 57(11):438, 440. PubMed ID: 12674858
    [No Abstract]   [Full Text] [Related]  

  • 45. HIV vaccine acceptability: a systematic review and meta-analysis.
    Newman PA; Logie C
    AIDS; 2010 Jul; 24(11):1749-56. PubMed ID: 20597165
    [TBL] [Abstract][Full Text] [Related]  

  • 46. NIAID HIV/AIDS vaccine research. National Institute of Allergy and Infectious Diseases.
    NIAID AIDS Agenda; 1997 Aug; ():4. PubMed ID: 11364611
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Trial-related discrimination in HIV vaccine clinical trials.
    Allen M; Israel H; Rybczyk K; Pugliese MA; Loughran K; Wagner L; Erb S
    AIDS Res Hum Retroviruses; 2001 May; 17(8):667-74. PubMed ID: 11429107
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Social impact of preventive HIV vaccine clinical trial participation: a model of prevention, assessment and intervention.
    Allen M; Lau CY
    Soc Sci Med; 2008 Feb; 66(4):945-51. PubMed ID: 18162272
    [TBL] [Abstract][Full Text] [Related]  

  • 49. HIV-1C vaccine trial planned for South Africa.
    Ramsay S
    Lancet; 2000 Oct; 356(9238):1336. PubMed ID: 11073034
    [No Abstract]   [Full Text] [Related]  

  • 50. Participation of homosexual/bisexual men in preventive HIV vaccine trials: baseline attitudes and concerns and predicted behaviors during trials.
    Douglas JM; Judson FN; Parks JP; Buchbinder S; McKirnan D
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S257-60. PubMed ID: 7865313
    [No Abstract]   [Full Text] [Related]  

  • 51. HIV, stigma, and rates of infection: a rumour without evidence.
    Reidpath DD; Chan KY
    PLoS Med; 2006 Oct; 3(10):e435. PubMed ID: 17076563
    [TBL] [Abstract][Full Text] [Related]  

  • 52. HIV vaccines--promise and directions.
    Kent SJ
    Med J Aust; 1999 Aug; 171(3):124-5. PubMed ID: 10474602
    [No Abstract]   [Full Text] [Related]  

  • 53. Understanding the efficacy variables of an HIV vaccine trial.
    Esparza J
    Lancet Infect Dis; 2012 Jul; 12(7):499-500. PubMed ID: 22652343
    [No Abstract]   [Full Text] [Related]  

  • 54. Using surrogate vaccines to assess feasibility and acceptability of future HIV vaccine trials in men: a randomised trial in inner-city Johannesburg, South Africa.
    Chimoyi L; Kamndaya M; Venables E; von Knorring N; Stadler J; MacPhail C; Chersich MF; Rees H; Delany-Moretlwe S
    BMC Public Health; 2017 Jul; 17(Suppl 3):524. PubMed ID: 28832280
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Motivators of enrolment in HIV vaccine trials: a review of HIV vaccine preparedness studies.
    Dhalla S; Poole G
    AIDS Care; 2011 Nov; 23(11):1430-47. PubMed ID: 21722022
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Recruitment, screening and characteristics of injection drug users participating in the AIDSVAX B/E HIV vaccine trial, Bangkok, Thailand.
    Vanichseni S; Tappero JW; Pitisuttithum P; Kitayaporn D; Mastro TD; Vimutisunthorn E; van Griensvan F; Heyward WL; Francis DP; Choopanya K;
    AIDS; 2004 Jan; 18(2):311-6. PubMed ID: 15075550
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Not if but how? Caring for HIV-1 vaccine trial participants in South Africa.
    Tucker T; Slack C
    Lancet; 2003 Sep; 362(9388):995. PubMed ID: 14513854
    [No Abstract]   [Full Text] [Related]  

  • 58. Controlling and ultimately ending the HIV/AIDS pandemic: a feasible goal.
    Folkers GK; Fauci AS
    JAMA; 2010 Jul; 304(3):350-1. PubMed ID: 20639573
    [No Abstract]   [Full Text] [Related]  

  • 59. First AIDS vaccine tested did not protect, but gives scientific leads.
    James JS
    AIDS Treat News; 2003 Mar; (389):6. PubMed ID: 12712937
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Canadians, Gates unite to conduct AIDS vaccine research.
    AIDS Policy Law; 2007 Mar; 22(5):2. PubMed ID: 17387798
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.